Journal article
Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer
JNCI : Journal of the National Cancer Institute
07 Mar 2026
PMID: 41795824
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background
This population-based study aimed to quantify fracture risk after androgen receptor pathway inhibitors in advanced prostate cancer patients by preexisting health conditions.
Methods
Patients were identified from the Surveillance, Epidemiology, and End Results-Medicare files who received abiraterone acetate with prednisone or enzalutamide between January 1, 2013, and December 31, 2020. Health and fracture history were based on claims 1 year before androgen receptor pathway inhibitor with follow-up through December 31, 2020. The main outcome of the study was the cumulative fracture risk after first date of androgen receptor pathway inhibitor. Fine and Gray subdistribution hazard model was used to obtain adjusted relative risks with confounding factors.
Results
This study included 10 463 patients (6037 treated with abiraterone acetate with prednisone; 4426 treated with enzalutamide). The 3-year fracture risk after androgen receptor pathway inhibitor was high, exceeding 25% among those without a prior fracture. Among 1445 men with a fracture the year before androgen receptor pathway inhibitor, 3-year fracture risk exceeded 50% and remained high (above 44%) despite using bone health agents. A recent history of fracture was associated with a 2.84-fold fracture risk (adjusted hazard ratio [HR] = 2.84, 95% confidence interval [CI] = 2.58 to 3.12). Preexisting osteoporosis and a comorbidity score of 2 or higher were associated with 15% (adjusted HR = 1.15, 95% CI = 1.03 to 1.29) and 11% (adjusted HR = 1.11, 95% CI = 1.00 to 1.24) higher fracture risks. Bone health agent use was associated with a 23% lower fracture risk (adjusted HR = 0.77, 95% CI = 0.70 to 0.83).
Conclusions
Fracture risk after androgen receptor pathway inhibitor was high, exceeding 44% within 3 years in those with prior fractures despite bone health agents, suggesting limited benefit in patients with poor bone quality. Early identification and intervention for patients at high risk of fractures are critical.
Metrics
1 Record Views
Details
- Title
- Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer
- Creators
- Grace Lu-Yao - Sidney Kimmel Cancer CenterNikita Nikita - Thomas Jefferson UniversityScott W. Keith - Thomas Jefferson UniversityKrupa Gandhi - Thomas Jefferson UniversityAmy L. Shaver - Thomas Jefferson UniversitySwapnil Sharma - Thomas Jefferson UniversityChristina Steinbock-Malfer - Thomas Jefferson UniversityHushan Yang - Thomas Jefferson UniversityChristopher Yang - Drexel University, Information ScienceKevin K. Zarrabi - Thomas Jefferson UniversityStephen J. Freedland - Cedars-Sinai Medical CenterWilliam K. Kelly - Thomas Jefferson University
- Publication Details
- JNCI : Journal of the National Cancer Institute
- Publisher
- Oxford Univ Press
- Number of pages
- 9
- Grant note
- Award W81XWH-22-1-0582 NIH Grant 1R01-CA255792-01A1 / Department of Defense; United States Department of Defense NCI/NIH Cancer Center Support Grant 5P30CA056-036 / Biostatistics and Bioinformatics shared resources at the Sidney Kimmel Comprehensive Cancer Center at Jefferson PA CURE Award SAP # 4100088563 / PA Department of Health
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Information Science
- Web of Science ID
- WOS:001740663200001
- Other Identifier
- 991022180702804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology